Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway

Cancer Biology and Therapy

Volumn 8, Issue 18, 2009, Pages 1729-1736

  Peng, Chang Liang ^a   Guo, Wei ^a   Ji, Tao ^a   Ren, Tingting ^a   Yang, Yi ^a   Li, Da Sen ^a   Qu, Hua Yi ^a   Li, Xiao ^a   Tang, Shun ^a   Yan, Tai Qiang ^a   Tang, Xiao Dong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Cell cycle; HS SY II; MAPK; Sorafenib; SW982; Synovial sarcoma

Indexed keywords

CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RAF PROTEIN; RETINOBLASTOMA PROTEIN; SORAFENIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NICK END LABELING; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TUMOR GROWTH;

EID: 72449133456     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.18.9208     Document Type: Article

References (50)

1. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62:135-40.
2. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 2002; 133:1-23.
3. dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Gene Chromosome Canc 2001; 30:1-14.
4. McCarville MB, Spunt SL, Skapek SX, Pappo AS. Synovial sarcoma in pediatric patients. AJR Am J Roentgenol 2002; 179:797-801.
5. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101:627-34.
6. Fernebro J, Francis P, Edén P, Borg A, Panagopoulos I, Mertens F, et al. Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 2006; 118:1165-72.
7. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001; 20:5755-62.
8. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, et al. Identification of novel genes, SYT and SSX, involved in the t(X; 18) (p11.2; q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7:502-8.
9. de Leeuw B, Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial. Hum Mol Genet 1995; 4:1097-9.
10. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995; 14:2333-40.
11. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlén M, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999; 91:974-5.
12. Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007; 246:105-13.
13. Mullen JR, Zagars GK. Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 1994; 33:23-30.
14. Sakabe T, Murata H, Konishi E, Takeshita H, Ueda H, Matsui T, et al. Evaluation of clinical outcomes and prognostic factors for synovial sarcoma arising from the extremities. Med Sci Monit 2008; 14:305-10.
15. Bessard A, Frémin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008; 27:5315-25.
16. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 2008; 60:261-310.
17. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 2008; 13:459-66.
18. Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006; 19:541-7.
19. Hahn O, Stadler W Sorafenib. Curr Opin Oncol 2006; 18:615-21.
20. Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109.
21. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-93.
22. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271:20608-16.
23. Xie YT, Skytting B, Nilsson G, Grimer RJ, Mangham CD, Fisher C, et al. The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X; 18) (p11.2; q11.2) and the cell cycle machinery. Oncogene 2002; 21:5791-6.
24. Horvai AE, Kramer MJ, O'Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 2006; 130:792-8.
25. Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH. Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Eukaryot Gene Expr 2008; 18:11-33.
26. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7.
27. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27:6398-406.
28. Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma. A clinicopathological study of 136 cases. Cancer 1977; 39:1201-17.
29. Pack GT, Ariel IM. Synovial sarcoma (malignant synovial sarcoma): a report of 60 cases. Surgery 1950; 28:1047-84.
30. Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 2007; 63:111-24.
31. Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005; 103:830-8.
32. Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol 2007; 38:914-25.
33. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal 2003; 15:463-9.
34. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 2008; 60:261-310.
35. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008; 9:747-58.
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310.
37. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007; 26:3159-71.
38. Ng R, Chen EX. Sorafenib (BAY 43-9006): review of clinical development. Curr Clin Pharmacol 2006; 1:223-8.
39. Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology 2007; 73:204-9.
40. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006; 169:1875-85.
41. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12:9-18.
42. Kiyokama H, Richon VM, Rifkind RA, Marks PA. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol 1994; 14:7195-203.
43. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999; 274:22013-8.
44. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35:796-807.
45. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997; 20:245-67.
46. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281:1322-6.
47. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7:989-1000.
48. Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 2008; 27:6419-33.
49. th Annual Meeting of the American-Association-for-Cancer-Research. Washington, Dc: Landes Bioscience 2003; 1137-42.
50. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000; 33:261-74.